Co-led Actithera's oversubscribed $75.5M Series A for FAP-targeting radiopharmaceutical therapies.
Actithera is a biotech company focused on developing targeted radioligand therapies for cancer, aiming to deliver personalized treatments with fewer side effects
Actithera is a biotech company focused on developing targeted radioligand therapies for cancer, aiming to deliver personalized treatments with fewer side effects.